Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...

Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private ...

Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of ...

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...

Biocon Biologics launches Yesintek biosimilar to Stelara in US: Our Bureau, Bengaluru Tuesday, February 25, 2025, 15:40 Hrs [IST] Biocon Biologics has announced that Yesintek (ust ...

Walgreens said it had entered into a settlement agreement with telemedicine provider Everly Health Solutions as part of which ...

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

Eli Lilly will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells ...

Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients: Basel Tuesday, February 25, 2025, 14:00 Hrs [IST] Sandoz, the global leader in ge ...